HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Masanori Noguchi Selected Research

Estramustine

4/2011A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low-dose estramustine in HLA-A24-positive patients with castration-resistant prostate cancer.
7/2010A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer.
1/2007Combination therapy of personalized peptide vaccination and low-dose estramustine phosphate for metastatic hormone refractory prostate cancer patients: an analysis of prognostic factors in the treatment.
4/2005Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients.
6/2004Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer.
2/2004Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Masanori Noguchi Research Topics

Disease

56Neoplasms (Cancer)
05/2020 - 07/2003
54Prostatic Neoplasms (Prostate Cancer)
01/2021 - 09/2002
6Renal Cell Carcinoma (Grawitz Tumor)
08/2015 - 03/2007
4Disease Progression
01/2021 - 08/2003
4Carcinoma (Carcinomatosis)
12/2017 - 12/2006
4Melanoma (Melanoma, Malignant)
04/2015 - 07/2003
4Neoplasm Metastasis (Metastasis)
02/2005 - 05/2003
2Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2016 - 05/2012
2Pancreatic Neoplasms (Pancreatic Cancer)
09/2013 - 09/2010
2Kidney Neoplasms (Kidney Cancer)
06/2011 - 02/2009
1Urologic Neoplasms (Urological Cancer)
09/2018
1Small Cell Lung Carcinoma (Small Cell Lung Cancer)
11/2017
1Urinary Bladder Neoplasms (Bladder Cancer)
01/2016
1Neuroblastoma
04/2015
1Hepatocellular Carcinoma (Hepatoma)
01/2015
1Biliary Tract Neoplasms (Biliary Tract Cancer)
05/2013
1Stomach Neoplasms (Stomach Cancer)
01/2011
1Injection Site Reaction
01/2011
1Cellulitis
01/2011
1Colitis
01/2011
1Hemorrhage
01/2011
1Lymphoma (Lymphomas)
12/2009
1Mental Disorders (Mental Disorder)
11/2009
1Bipolar Disorder (Manic Depressive Psychosis)
11/2009
1Lower Urinary Tract Symptoms
09/2008

Drug/Important Bio-Agent (IBA)

69Peptides (Polypeptides)IBA
01/2021 - 05/2003
24AntigensIBA
05/2020 - 07/2003
20Protein Subunit VaccinesIBA
12/2017 - 10/2005
18Cancer VaccinesIBA
05/2020 - 12/2006
15Immunoglobulin G (IgG)IBA
11/2015 - 07/2003
13HLA Antigens (Human Leukocyte Antigens)IBA
09/2018 - 01/2004
12VaccinesIBA
01/2016 - 07/2003
10HLA-A2 Antigen (HLA A2 Antigen)IBA
11/2015 - 07/2003
10HLA-A24 AntigenIBA
09/2010 - 07/2003
8EpitopesIBA
11/2015 - 08/2003
7Prostate-Specific Antigen (Semenogelase)IBA
09/2018 - 05/2003
7Hormones (Hormone)IBA
12/2008 - 09/2003
6EstramustineFDA Link
04/2011 - 02/2004
6HLA-A3 Antigen (HLA A3 Antigen)IBA
09/2010 - 10/2005
5Biomarkers (Surrogate Marker)IBA
01/2020 - 02/2004
5Phosphates (Orthophosphate)IBA
04/2011 - 02/2004
4Docetaxel (Taxotere)FDA Link
01/2021 - 06/2012
3HLA-A*26 antigenIBA
10/2015 - 11/2009
3Proteins (Proteins, Gene)FDA Link
08/2015 - 07/2005
3HLA-A Antigens (HLA-A)IBA
01/2011 - 02/2009
3HLA-A11 AntigenIBA
02/2009 - 10/2005
3HLA-A31 antigenIBA
02/2009 - 10/2005
3HLA-A*33 antigenIBA
02/2009 - 10/2005
3Polycomb-Group ProteinsIBA
11/2007 - 09/2004
2Dexamethasone (Maxidex)FDA LinkGeneric
05/2020 - 12/2008
2prostatic acid phosphataseIBA
09/2018 - 09/2004
2PlatinumIBA
12/2017 - 01/2016
2Immune Checkpoint InhibitorsIBA
01/2017 - 05/2013
2SuspensionsIBA
09/2008 - 01/2004
2Enhancer of Zeste Homolog 2 ProteinIBA
11/2007 - 09/2004
2Androgen Receptors (Androgen Receptor)IBA
08/2007 - 11/2006
2Messenger RNA (mRNA)IBA
03/2007 - 12/2006
1Plant ExtractsIBA
12/2017
1keishibukuryoganIBA
12/2017
1bu-zhong-yi-qi-tangIBA
12/2017
1Cyclophosphamide (Cytoxan)FDA LinkGeneric
02/2016
1HaptoglobinsIBA
12/2015
1Lymphocyte Specific Protein Tyrosine Kinase p56(lck) (p56 lck)IBA
11/2015
1src-Family KinasesIBA
11/2015
1Biological ProductsIBA
08/2015
1Monoclonal AntibodiesIBA
08/2015
1Type II DNA Topoisomerases (Topoisomerase II)IBA
08/2015
1trioctyl phosphine oxide (TOPO)IBA
08/2015
1Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link
08/2015
1Proliferating Cell Nuclear Antigen (PCNA)IBA
04/2015
1ErythropoietinFDA Link
04/2015
1EphB6 ReceptorIBA
04/2015
1Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
04/2015
1Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
04/2015
1Therapeutic UsesIBA
05/2013
1Aldehyde Dehydrogenase 1 FamilyIBA
01/2013
1Vinblastine (Vinblastine Sulfate)FDA Link
09/2011
1Cisplatin (Platino)FDA LinkGeneric
09/2011
1Doxorubicin (Adriamycin)FDA LinkGeneric
09/2011
1Methotrexate (Mexate)FDA LinkGeneric
09/2011
1Sunitinib (Sutent)FDA Link
01/2011
1GemcitabineFDA Link
09/2010
1TubulinIBA
09/2010
1DNA (Deoxyribonucleic Acid)IBA
11/2009
1HLA-A*02:01 antigenIBA
11/2009
1HLA-A*26:01 antigenIBA
11/2009
1HLA-A*26:03 antigenIBA
11/2009
1Papillomavirus Vaccines (HPV Vaccines)IBA
02/2009
1vitespinIBA
02/2009
1Heat-Shock Proteins (Heat-Shock Protein)IBA
02/2009
1GlucocorticoidsIBA
12/2008
1Ethanol (Ethyl Alcohol)IBA
09/2008
1HLA-G Antigens (HLA G)IBA
12/2007

Therapy/Procedure

20Immunotherapy
01/2017 - 07/2003
17Castration
05/2020 - 07/2010
11Prostatectomy (Retropubic Prostatectomy)
04/2015 - 09/2002
11Therapeutics
09/2011 - 09/2002
8Drug Therapy (Chemotherapy)
12/2017 - 02/2009
1Aftercare (After-Treatment)
06/2012
1Radiotherapy
12/2009